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Abstract
Background: Data on the epidemiology and cost of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in Italy
are limited. This retrospective, population-based study was designed to determine the incidence of HZ and the
proportion developing PHN in Italy and the associated medical resource utilisation and costs. It focused primarily
on immunocompetent patients aged ≥50 years who would be eligible for preventive vaccination.
Method: Data were extracted from a primary-care database and national hospital-discharge records covering four
major regions in Italy for 2003-2005. Cases of HZ and PHN (1 and 3 months’ duration; PHN1 and PHN3) were
identified by ICD9-CM codes and, additionally for PHN, prescription of neuropathic pain medication.
Results: Over 3 years, 5675 incident cases of HZ were documented in adults, of which 3620 occurred in
immunocompetent patients aged ≥50 years (incidence of 6.31 per 1000 person-years [95% CI: 6.01-6.62]). Of the
immunocompetent patients aged ≥50 years with HZ, 9.4% (95% CI: 8.2-10.7) and 7.2% (95% CI: 6.2-8.2) developed
PHN1 and PHN3, respectively. Increasing age, female sex, and being immunologically compromised conferred
increased risk for both HZ and PHN. Overall, about 1.3% of HZ and almost 2% of PHN cases required inpatient care,
with 16.9% of all HZ-related hospitalisations due specifically to PHN. In patients aged ≥50 years, mean stay was
7.8 ± 5.4 days for HZ and 10.2 ± 8.6 days for PHN, and direct costs associated with inpatient care were more than
20 times outpatient costs per HZ case (mean ± SD: €2592 ± €1313 vs. €122.68 ± €97.51) and over 5 times more
per episode of PHN (mean ± SD: €2806 ± €2641 vs. €446.10 ± €442.97). Total annual costs were €41.2 million, of
which €28.2 million were direct costs and €13.0 million indirect costs.
Conclusions: This study, the largest to date on the epidemiology and economic impact of HZ and PHN in Italy,
confirms the considerable disease and economic burden posed by HZ. As HZ and PHN disproportionately affect
the elderly, without intervention this problem is likely to grow as the proportion of elderly in the Italian population
continues to increase.
Background
Herpes zoster (HZ), caused by reactivation of latent var-
icella zoster virus present in the dorsal root ganglia, is
an acute disease characterised by a vesicular rash. The
lifetime risk of developing HZ is about 20-30% [1-3].
However, the risk rises markedly with age, approxi-
mately doubling for each decade after 50 years of age
[4]. This age-related increase in HZ, which can occur
decades after primary varicella zoster infection, is due to
a varicella zoster virus-specific decline in cell-mediated
immunity with increasing age [5].
While pain associated with the acute infection tends
to resolve with the rash, post-herpetic neuralgia (PHN),
an intractable pain in the dermatome affected by HZ,
remains a common complication. Precise definitions of
PHN vary, but it is estimated to affect 10-20% of all
patients with HZ aged >50 years [6-8] and up to 30% of
those aged ≥80 years [6]. Pain associated with acute HZ
infection and more especially PHN causes distress and
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over, the management of HZ and particularly PHN, the
most common complication in the elderly, is often
suboptimal [15,16].
After Japan, Italy has the highest proportion of elderly
people in its population [17], and yet data on the epide-
miology of HZ and PHN in Italy and the associated
costs are limited. An observational study carried out a
decade ago in Italy noted an incidence of 4.14 per 1000
population (aged ≥15 years) per year. In that study, over
75% of all HZ cases occurred in those aged ≥50 years,
with about 50% occurring in the ≥65-year age group
[18]. A more recent prospective Italian study found an
annual incidence of 1.59 per 1000 population (aged ≥15
years), and calculated a mean cost for each HZ case
treated in the outpatient setting of €360.60 and for each
hospitalised case of €4082.59 [19].
The present study was designed to provide additional
data on the incidence of HZ and to determine the pro-
portion of HZ cases developing PHN in Italy. The study
also sought to determine the associated medical
resource utilisation and costs, and to estimate the total
economic burden of HZ and PHN in Italy. Both parts of
the study focused on the immunocompetent population
aged ≥50 years, who would be eligible to receive a pre-
ventive vaccine that will be available soon in the Eur-
opean Union.
Methods
Study design
This was a retrospective, population-based study in
which epidemiological and economic data were esti-
mated in adult men and women, primarily aged ≥50
years, from a large primary-care database and national
hospital-discharge records.
Data sources
Primary-care data were obtained from the Health Search
Database (HSD) of the Società Italiana Medici Generici
(SIMG) for the period 2003-2005. Established in 1998,
and with the input of general practitioners (GPs) who
accept to participate on a voluntary basis, the SIMG
database contains demographic data, medical diagnoses
(coded according to the International Classification of
Diseases, 9
th Revision, Clinical Modification [ICD9-
CM]), drug prescriptions (coded according to the Ana-
tomical Therapeutic Chemical [ATC] classification sys-
tem), hospital referrals and diagnostic investigations for
over 1 million patients [20,21]. This database has been
set up by SIMG with the primary aim of carrying out
observational studies on incidence and prevalence, as
well as studies on drug safety and prescriptions. Data
are recorded in the HSD with the consent of the patient,
lawfully stored, managed according to privacy rules and
can be used for scientific studies without any further
authorization from an ethics committee.
The HSD, at the beginning of 2006, contained informa-
tion from over 600 GPs, who were working in the national
public health system, and were from the three major Ita-
lian geographical areas (Northern, Central, Southern Italy).
The present study included a sample of 342 of these GPs
who had contributed medical records to the HSD between
2003-2005. All physicians met standard quality criteria for
the HSD [21]. Their geographic distribution mirrored the
total population of these three geographical areas (152
from Northern Italy, 64 from Central Italy, and 126 from
Southern Italy). The 342 physicians participating in this
study represented around 0.8% of the total number of Ita-
lian GPs, covering approximately 450,000 patients, of
which about 200,000 were aged ≥50 years.
Each participating GP underwent formal training for
data entry and used standard software to record data. A
unique patient code links demographic and prescription
information, clinical events and diagnoses, hospital
admission, and cause of death. Data were subject to a
range of quality checks.
The primary-care data were supplemented with data
from hospital-discharge registries for the period 2003-
2005 to determine hospitalisations due to HZ and PHN.
Established in 1995 and covering all regions of Italy, the
registries use a standard discharge form (Scheda di Dis-
missione Ospedaliera; SDO) to document patient demo-
graphic data, admission and discharge dates, discharge
status, diagnostic/therapeutic procedures, discharge pri-
mary and secondary diagnoses (coded according to
ICD9-CM), and in-hospital transfers. The SDO is the
main source of information about hospital admissions in
Italy, and all hospital discharges must also be registered,
since SDO data contribute to the determination of the
appropriate DRG and computation of the reimburse-
ment fee for each hospitalization. Analogous to the
HSD, the SDO data are also recorded with the consent
of the patient, and can be used as aggregated data for
scientific studies without further authorizations.
For the purpose of this study, registries of a represen-
tative sample of four regions (Veneto, Toscana, Lazio
and Campania), which account for about 30% of the Ita-
lian population, were analysed. These regions were cho-
sen as they mirror the three main Italian geographical
areas (Northern, Central, and Southern Italy).
Case definitions used to identify HZ cases in the
databases
The overall population of patients included in the ana-
lyses of primary-care data were those diagnosed with
HZ in years 2003-2005 as defined by ICD9-CM codes
(Table 1). To identify the immunocompetent subpopu-
lation, we excluded patients with HZ who had received
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period of more than 3 months, and those who had
been given the following ICD9-CM codes indicative of
immunodeficiency; 042 (human immunodeficiency
virus), 140-171, 174-208, and 235-239 (malignancies),
279 (congenital immunodeficiency) and V42 (organ or
tissue replaced by transplant). The same case definition
was used to identify HZ cases in the hospital-discharge
registries.
Case definitions used to identify PHN cases in the
databases
To capture PHN cases seen by a GP in the SIMG data-
base who may not have been recoded from HZ to PHN,
patients were included if they had an ICD9-CM code
for PHN (Table 1), or an ICD9-CM code for HZ and a
prescription for any drug commonly prescribed for
PHN, such as opioids, antiepileptics, tricyclic antidepres-
sants (TCAs) or local anaesthetics (Table 2). Because
there is no international consensus on the duration of
pain in PHN, two definitions of PHN were used for
cases identified in the SIMG database. PHN at 1 month
(PHN1) or PHN at 3 months (PHN3) included all HZ
cases that had been treated at least once with one or
more of the aforementioned drugs during the period 1-
12 months or 3-12 months after HZ diagnosis, respec-
tively, or had an ICD9-CM PHN code recorded within
the same time frame.
PHN cases were identified in the SDO databases as
those with an ICD9-CM code for PHN (053.12, 053.13,
or 053.19).
Statistical analyses
Estimates of HZ and proportion of patients with HZ
developing PHN
As short-term recurrences of HZ are very uncommon
among immunocompetent patients, all cases were
assumed to be incident cases. Incidence of HZ was cal-
culated as the number of cases in relation to the popula-
tion at risk at the beginning of each calendar year (2003,
2004, 2005), defined as the total patient population
registered with the 342 primary-care practices. The pro-
portion of patients with HZ who developed PHN
(PHN1 or PHN3) was calculated. Estimates were
obtained for immunocompetent patients aged ≥50 years
(primary analyses), for the whole adult population, and
in relation to sex and immune status and by age group.
Table 1 International Classification of Diseases (ICD9-CM) Codes for Herpes Zoster and Related Complications
Code Number Medical Term
053 Herpes zoster (includes shingles zona)
053.0 Herpes zoster with meningitis
053.1 Herpes zoster with other nervous system complications
053.10 Herpes zoster with unspecified nervous system complication
053.11 Geniculate herpes zoster/Herpetic geniculate ganglionitis
053.12 Post-herpetic trigeminal neuralgia
053.13 Post-herpetic polyneuropathy
053.19 Other
053.2 Herpes zoster with ophthalmic complications
053.20 Herpes zoster dermatitis of eyelid/herpes zoster ophthalmicus
053.21 Herpes zoster keratoconjunctivitis
053.22 Herpes zoster iridocyclitis
053.29 Other
053.7 Herpes zoster with other specified complications
053.71 Otitis externa due to herpes zoster
053.79 Other
053.8 Herpes zoster with unspecified complication
053.9 Herpes zoster without mention of complication (also known as herpes zoster NOS)
NOS = not otherwise specified
Table 2 Anatomical Therapeutic Chemical (ATC) Codes
Used to Identify PHN Cases in the SIMG Database
ATC Code Drug Class Drugs
N02A Opioids Tramadol
N03 Antiepileptics Phenytoin
Carbamazepine
Gabapentin
Pregabalin
N06A Antidepressants Amitriptyline
Nortriptyline
Imipramine
Desipramine
N01B Local Capsaicin cream
anaesthetics Lidocaine
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years (or incidence in the whole adult population) was
extrapolated, by applying appropriate multiplication fac-
tors, to provide estimates of the annual number of cases
of HZ or PHN for the total immunocompetent popula-
tion aged ≥50 years (or total adult population) in Italy.
Population sizes were obtained from the Italian National
Institute of Statistics (ISTAT) website [22].
Rates of hospitalisation for HZ and PHN (immuno-
competent patients only) were calculated as the number
of hospitalisations for HZ and PHN, extracted from the
SDOs, in relation to the population at risk. The popula-
tion at risk constituted the resident population in each
of the four regions, with figures obtained for the period
2003-2005 from the ISTAT website [22].
Univariate and multiple Poisson models, with age
group, sex, immune status, region and calendar year as
covariates, were used to identify factors associated with
an increased risk of acquiring HZ and PHN. As assumed
for a poisson model our response variable is a count
v a r i a b l e[ i . e . ,0n oH Z( o r0n oP H N ) ,1H Z( o rP H N ) ] .
For each year of the study period, each subject was con-
sidered exposed for the entire year. Crude and adjusted
incidence rate ratios were estimated from these models
given that the poisson regression coefficients are the
logarithm of the rate ratio. Given that the study design
was a two-stage design because data from primary care
were clustered by GPs, and those from hospitalisations
were clustered by region, the reported 95% confidences
intervals were calculated by taking into account the fact
that people were clustered within GP practices (for the
primary care data) and within region (for the hospitali-
sation data) [23]. The analyses were performed using
Stata software (version 9.0).
Estimation of medical resource use and direct and indirect
costs associated with HZ and PHN in immunocompetent
patients aged ≥50 years
Medical resource consumption for outpatient care in
immunocompetent patients aged ≥50 years was
extracted from the SIMG database for the period 2003-
2005. The follow-up period for cases of HZ was 1
month from diagnosis, while cases of PHN were fol-
lowed for at least 6 months from initial diagnosis. Esti-
mated unit costs for outpatient visits, diagnostic tests
and procedures were based on the average actual cost of
each visit/test/procedure across all individual records in
the SIMG database in 2005. Costs of medication for HZ
and PHN were calculated based on drug prices in the
2005 edition of the Prontuario Farmaceutico Nazionale
(PFN) [24]. The amount of resource use and the unit
costs were used to calculate the costs of outpatient care
per episode of HZ and PHN.
Medical resource consumption and costs for inpatient
admissions and hospital day care between 2003 and
2005 in immunocompetent patients aged ≥50 years were
obtained from the hospital-discharge registries. Hospital
costs were expressed in 2005 prices using the general
price index before aggregating all direct costs.
The overall direct costs of HZ and PHN were calcu-
lated by multiplying the mean cost of each case with the
expected total number of cases in the Italian population.
Indirect costs associated with HZ and PHN were
based on likely productivity losses for individuals aged
50-64 years. A focus group of experts, including a neu-
rologist, a geriatrist, a dermatologist and a pain specia-
list, led by an external moderator, reached a consensus
on the number of working days lost due to HZ or PHN.
Average daily wage data were taken from Consiglio
Nazionale dell’Economia e del Lavoro (CNEL) labour
cost statistics [25] and workforce participation rates
from ISTAT data [22]. Indirect costs were expressed in
2005 prices using the general price index.
Estimates of the economic burden of HZ and PHN in the
immunocompetent population aged ≥50 years
Total cost per episode of HZ and PHN was estimated
from both the third-party payer and societal perspective.
The economic burden of HZ and PHN (calculation
restricted to PHN1, as PHN1 and PHN3 were only dis-
tinguishable in the outpatient setting) was calculated as
the sum of the estimated total outpatient costs, total
hospitalisation costs, and total indirect costs (productiv-
ity loss) described above.
Results
Epidemiological analysis
HZ incidence
In total, 5675 incident cases of HZ were documented
over the 3-year study period, with 1843, 1898 and 1934
cases recorded in 2003, 2004 and 2005, respectively.
Patients aged ≥50 years accounted for 4119 (72.6%) inci-
dent cases, of which 3620 (87.9%) occurred in immuno-
competent patients. Among men and women aged ≥50
years, this corresponded to an incidence of 6.65 per
1000 person-years (95% CI: 6.35-6.97), or 6.31 per 1000
person-years (95% CI: 6.01-6.62) in the immunocompe-
tent population. In comparison, the incidence was 4.31
per 1000 person-years (95% CI: 4.11-4.52) for the adult
population as a whole, or 4.07 per 1000 person-years
(95% CI: 3.88-4.27) for the immunocompetent adult
population. Incidence increased markedly with age, with
the peak occurring in those aged 75-79 years (Figure 1).
HZ was more common among women than men in the
total population, with an incidence of 4.75 (95% CI:
4.47-5.03) compared with 3.82 (95% CI: 3.62-4.03) per
1000 person-years, respectively.
In the multivariate analysis, classical risk factors
(female sex, age ≥55 years, and being immunologically
compromised) were found to be independently
Gialloreti et al. BMC Infectious Diseases 2010, 10:230
http://www.biomedcentral.com/1471-2334/10/230
Page 4 of 11associated with an increased risk of acquiring HZ
infection.
Projected number of HZ cases per year
With over 22 million people aged ≥50 years living in
Italy in 2005 [22], 139,435 new cases of HZ can be
expected to occur annually in immunocompetent people
aged ≥50 years. A total of 157,100 cases would be
expected in all people aged ≥50 years, which represents
72.6% of the 216,391 cases expected for the adult popu-
lation as a whole. Italian primary-care physicians, who
have an average patient registry of 1283, can expect to
see between 5 and 6 new cases of HZ per year.
Proportion of patients with HZ who developed PHN
In total, 452 cases of PHN1 were documented in the
adult population over the 3-year study period, of which
350 (77.4%) cases also met criteria for PHN3. Thus,
8.0% (452/5675) (95% CI: 7.0-8.9) of the adult popula-
tion with HZ experienced PHN lasting at least 1 month
and 6.2% (350/5675) (95% CI: 5.3-7.0) experienced PHN
for at least 3 months. The proportion of patients with
HZ who developed PHN was highest in those aged ≥50
years (Figure 2), with these older patients accounting for
91.2% (412/452) of all cases of PHN1 and 90.9% (318/
350) of all cases of PHN3. The PHN1 proportion and
PHN3 proportion were similar for all HZ patients aged
≥50 years (10.0% [412/4119] [95% CI: 8.8-11.2] and 7.7%
[318/4119] [95% CI: 6.6-8.8], respectively) and the
immunocompetent HZ patients aged ≥50 years (9.4%
[342/3620] [95% CI: 8.2-10.7] and 7.2% [261/3620] [95%
CI: 6.2-8.2], respectively).
PHN was more common in women than in men with
HZ. In the adult population as a whole, the proportion
of women vs. men with HZ who developed PHN was
8.9% (294/3296) (95% CI: 7.7-10.2) vs. 6.6% (158/2379)
(95% CI: 5.5-7.7) for PHN1 and 6.9% (228/3296) (95%
CI: 5.8-8.0) vs. 5.1% (122/2379) (95% CI: 4.1-6.1) for
PHN3. Over 65% of cases of both PHN1 and PHN3 in
primary care were documented in female patients.
In the multivariate analysis, classical risk factors
(female sex, increasing age [>60 years], and being immu-
nologically compromised) were found to be indepen-
dently associated with an increased risk of developing
PHN.
Hospitalisation for HZ and PHN
Over the 3-year study period, the average incidences of
hospitalisation for primary diagnoses of HZ and PHN
were 10.34 and 1.89 per 100,000 person-years, respec-
tively, in immunocompetent patients aged ≥50 years.
The total incidence rose to 20.31 per 100,000 person-
years (17.45 for HZ and 2.86 for PHN) in this popula-
tion when both primary and secondary diagnoses on
SDOs were combined. Corresponding figures for the
adult immunocompetent population as a whole were
5.55 per 100,000 person-years for a primary diagnosis
(4.61 for HZ and 0.94 for PHN) and 9.60 per 100,000
person-years for primary and secondary diagnoses
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Page 5 of 11combined (7.94 for HZ and 1.66 for PHN). Within the
older population, rates of hospitalisation increased pro-
gressively for each decade up to 85 years (Figure 3).
Based on these figures, HZ or PHN as a primary diagno-
s i si sr e s p o n s i b l ef o r2 8 2 9h ospitalisations annually in
Italy among the immunocompetent adult population, of
which 2611 (92.3%) admissions are in those aged ≥50
years. When primary and secondary diagnoses are com-
bined, about 1.3% of HZ cases in Italy result in hospita-
lisation, rising to almost 2% where patients develop
PHN. Overall, 16.9% of hospitalisations related to HZ
were due specifically to PHN.
Economic analysis
Outpatient resource consumption
For immunocompetent patients aged ≥50 years, the
mean number of primary-care consultations for each
case of HZ was 1.9. In total, 17.7% (640/3620) of cases
were referred to a specialist (primarily ophthalmologists,
dermatologists or neurologists). The mean number of
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Page 6 of 11specialist visits was 0.2 for each case of HZ, increasing
slightly with age. Antivirals were used in 78.4% of cases,
while 12.2% were treated with anticonvulsants, 5.1%
with opioid analgesics, 3.2% with non-opioid analgesics
and 3.0% with TCAs. Overall, 28.0% (1012/3620) of
cases underwent further diagnostic or laboratory exami-
nations, with the mean number of procedures and
examinations being 2.6 for each case of HZ, increasing
with age (age class range 2.3-2.9).
For immunocompetent patients aged ≥50 years, the
mean number of primary-care consultations for each
case of PHN1 and PHN3 was 11.9 and 12.0, respectively.
In total, 74.1% (206/278) and 73.7% (154/209) of PHN1
and PHN3 cases were referred to a specialist (primarily
ophthalmologists, dermatologists or neurologists), with a
mean number of specialist visits of 3.5 for each case of
PHN1 (age class range 2.2-4.3) and 3.9 for each case of
PHN3 (age class range 2.5-4.7). Anticonvulsants were
prescribed in 51.4% and 46.4% of PHN1 and PHN3
cases, respectively. Corresponding figures for opioid
analgesics were 27.0% and 26.3% and for TCAs were
15.1% and 13.4%, respectively. Drug utilisation was
higher overall for cases of PHN3.
Direct costs - outpatient care
For immunocompetent patients aged ≥50 years, the
mean outpatient cost (±SD) for each case of HZ was
€122.68 ± €97.51 (at 2005 prices), of which 83.1% was
due to the cost of medications. Diagnostic radiology or
ophthalmological and otological examinations (6.8%),
laboratory investigations (6.6%) and specialist visits
(3.6%) accounted for the remaining costs.
For immunocompetent patients aged ≥50 years, the
mean outpatient cost (±SD) for each case of PHN1
was €446.10 ± €442.97 and for each case of PHN3 was
€416.65 ± €406.30 (at 2005 prices), of which laboratory
investigations and investigative procedures accounted
for 58.1% and 63.4% of total costs for PHN1 and
PHN3, respectively. Medications accounted for about a
quarter of total outpatient costs, at 27.7% and 21.5%
for PHN1 and PHN3, respectively. Specialist referral
was sought in 74.1% (206/278) of PHN1 cases and
73.7% (154/209) of PHN3 cases; these visits accounted
for the remaining 14.2% and 15.1%, respectively, of
total outpatient costs.
Hospital resource consumption
Of the total hospitalisations for HZ, 92.3% were related
to major skin disorders, eye disorders, infections of the
nervous system (excluding meningitis) and viral ill-
nesses. For immunocompetent patients aged ≥50 years,
the mean (±SD) inpatient stay for HZ was 7.8 ± 5.4
days, which increased with age (6.5 ± 5.5 days for 50-
54-year-olds vs. 8.9 ± 5.6 days for those aged >85 years).
Of the total hospitalisations for patients with PHN,
92.6% were related to cranial and peripheral nerve disor-
ders and infections of the nervous system (excluding
meningitis). For immunocompetent patients aged ≥50
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Page 7 of 11years, the mean (±SD) inpatient stay for PHN was 10.2
± 8.6 days and showed no age-related trend.
Direct costs - inpatient care
For immunocompetent patients aged ≥50 years who
were hospitalised, the mean cost (±SD) per patient of
inpatient care in the period 2003-2005 was €2592 ±
€1313 for HZ and €2806 ± €2641 for PHN.
Total direct costs per case
The mean direct medical cost per HZ episode in Italy
was calculated as €166, which comprised outpatient
costs of €123 per episode, to which €43 was added as
the mean cost of hospitalisation per HZ episode, com-
puted as the cost of hospitalisation spread over the total
number of expected cases (Table 3). The corresponding
mean direct medical cost of PHN (calculation restricted
to PHN1, as PHN1 and PHN3 were only distinguishable
in the outpatient setting) was calculated as €560 per epi-
sode (Table 3).
Indirect costs per case
Mean indirect costs for the immunocompetent popula-
tion aged ≥50 years were based on the following
assumptions: a workforce participation rate of 65.8% for
50-54-year-olds declining to 20.2% for 60-64-year-olds
and retirement at 65 years; an average daily wage of
€80; and an average loss of 7 and 10 working days for
HZ and PHN, respectively. Indirect costs were calcu-
lated at €556 and €795 per case of HZ and PHN,
respectively (Table 3).
Total costs
Based on an estimated 129,435 cases of HZ and 12,228
cases of PHN1 per annum in the immunocompetent
population aged ≥50 years, the total direct medical cost
of managing HZ infection and PHN in Italy was €28.2
million, of which €21.5 million was associated with the
treatment of acute HZ (Table 3). Outpatient costs
accounted for 75.2% of the total expenditure. Total
indirect costs were calculated as €13.0 million, of which
€12.2 million was attributed to acute HZ (Table 3). The
total annual economic burden of HZ and associated
PHN in the Italian immunocompetent population aged
≥50 years was €41.2 million, with almost a third of the
cost attributable to indirect costs associated with lost
productivity.
Discussion
This retrospective, population-based study represents
the largest investigation to date of the epidemiology and
economic impact of HZ and PHN in Italy. Drawing on a
primary-care database of over 450,000 patient records,
together with data from national hospital-discharge
records covering four major regions in Italy, our study
showed that the incidence of HZ in immunocompetent
individuals aged ≥50 years (6.31 per 1000 person-years),
the primary focus of the study, was comparable with
that reported in other studies [8,26], including an earlier
Italian study [18]. Furthermore, the incidence reported
here was consistent with recently published figures, for
the population aged ≥50 years, from the UK (5.23 per
1000 person-years) [6] and Australia (9.7 per 1000 per-
son-years) [7] despite some differences in study design.
However, our overall HZ incidence is higher than the
one recently published in Italy (4.31 vs. 1.59 per 1000
person-years) [19]. In common with these studies, HZ
incidence increased markedly with age up to 80 years.
In Italy, most patients with HZ consult their primary-
care physician [18] and so our data, retrieved from the
SIMG database, can be considered a reliable and robust
source for estimates of HZ incidence.
HZ incidence was more common in women than men,
a finding supported by several other studies [6,26-28],
albeit not all [4,29]. In addition to older age and
immune status, female sex was an independent risk fac-
tor for HZ, and indeed, for PHN as well. It is known
that immunosuppression predisposes patients to
increased risk of HZ and its complications [30]. It has
been suggested that women may have a different
immune response to latent viral infection and that this
may account for their increased risk compared with
men [27].
PHN, which in our study was identified by ICD9-CM
codes or prescriptions for specific neuropathic pain
medications, affected 9.4% of immunocompetent
Table 3 Costs Associated with HZ and PHN in Immunocompetent Patients Aged ≥50 years (at 2005 prices)
HZ PHN HZ plus PHN
Number of expected cases in Italian population per year 129,435 12,228 (PHN1 only*)
Mean € Total €m Mean € Total €m Total €m
Direct outpatient costs 123 15.9 446 5.3 21.2
Direct hospital costs 43 5.6 114 1.4 7.0
Total direct costs 166 21.5 560 6.7 28.2
Indirect costs 556 12.2 795 0.8 13.0
Total costs 33.7 7.5 41.2
HZ = herpes zoster; PHN = post-herpetic neuralgia
* Restricted to PHN1 because PHN1 and PHN3 were only distinguishable in the outpatient setting
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Page 8 of 11patients aged ≥50 years, of whom about 77% continued
to have pain 3 months after HZ onset. These rates are
consistent with those reported for several other commu-
nity-based studies [31-33]. However, they are consider-
ably lower than rates reported in clinical trials [34-36],
in other various studies [8,26] and, interestingly, in a
recent prospective study conducted in Piemonte in Italy
[19] and the recent UK General Practice Research Data-
base (UKGPRD) analysis [6], where 17.4% and 19.5% of
patients developed PHN1, respectively.
Certain limitations of this study may have resulted in
an underestimation of the proportion of PHN. In Italy,
primary-care physicians manage most cases of HZ but
only about a quarter of related cases of PHN because
most cases of PHN are managed by specialists. Thus,
this study did not capture cases of PHN that were not
seen by a primary-care physician or referred to hospital.
This demonstrates that use of the SIMG database to
evaluate PHN in Italy has limits as it excludes patients
who may have approached specialists directly. In addi-
tion, estimating the number of PHN cases retrospec-
tively on the basis of drug prescriptions for pain relief
rather than on the basis of pain severity may have led to
an underestimation of the proportion of HZ cases that
developed PHN because less serious cases which were
not treated with drugs and serious cases where patients
refused drug treatment may not have been detected.
While our estimates of HZ incidence are robust, those
for the proportion of patients with HZ who developed
PHN are less reliable and are probably underestimates.
Indeed, it is arguable that no study has produced reli-
able estimates of the proportion of HZ cases that
develop PHN, and this is exemplified by the variation
seen between studies [6,19,26,34,35]. Furthermore, in
retrospective studies based on data retrieved from large
databases, inaccuracies and, therefore, underestimations
due to incompleteness of data cannot be excluded. Pro-
spective studies, with patient follow-up, would provide a
more reliable approach to future estimates of the pro-
portion of patients with HZ developing PHN.
Some patients with HZ and PHN require hospital
treatment, including inpatient care. Overall, about 1.3%
of HZ cases required inpatient care in this study,
increasing to almost 2% where only PHN cases were
considered. At 9.60 per 100,000 person-years, the inci-
dence of hospitalisations for HZ or PHN was higher in
our study than rates reported in other European coun-
tries or North America [37,38] despite the exclusion in
our study of immunocompromised patients who consti-
tute those at greater risk of complications of HZ. In the
recent prospective study in Piemonte, the annual inci-
dence of hospitalisations for HZ was 0.12 per 1000
population [19]. Similar to the Piemonte study, age was
an important predictor of likely hospitalisation for HZ
or PHN in our study, with rates of hospitalisation
increasing progressively for each decade up to 85 years
of age, an observation that has also been reported pre-
viously [7]. Our data show a striking age-related increase
in hospitalisation due to both HZ and PHN whether as
a primary or secondary diagnosis.
We also estimated the economic impact of HZ and its
complications in terms of direct healthcare costs as well
as estimating likely indirect costs. As this study has
demonstrated, HZ and PHN, the most common compli-
cation of HZ, impose a significant economic burden on
the Italian population, with total costs for patients aged
≥50 years exceeding €41 million a year. At €28.2 million,
direct medical costs accounted for just over two-thirds
of total costs. Indirect costs associated with lost produc-
tivity were responsible for almost a third of total costs
in the older population and reflect the debilitating nat-
ure of HZ and PHN among older people of working
age. Although the recent prospective study in Piemonte
did not extrapolate data to obtain total direct costs for
the Italian population, at €136.06 per observed outpati-
ent case of HZ, €360.60 per case treated in the outpati-
ent setting, and €4082.59 for each hospitalised case
(€2499.67 where HZ was the principal diagnosis) direct
costs per case were broadly similar to our estimates [19].
Studies have consistently shown that HZ and espe-
cially PHN significantly impact patients’ quality of daily
life [9-14] and, moreover, are difficult to treat. Therapy
relies on antiviral drugs to address the underlying cause
of HZ and analgesia for pain relief in patients who
develop PHN. As this study has shown, medications
were responsible for over 80% of all direct outpatient
costs, a finding supported by other studies [6,39]. This
primary cost determinant may vary widely between
countries. In the present study 78% of patients received
antivirals, similar to the proportion reported for a recent
study in Australia, whereas less than 25% of patients
with HZ in The Netherlands receive antiviral therapy
[7,40]. If administered within 72 hours of the onset of
rash, antivirals have been shown to promote rash heal-
ing and reduce the intensity and pain of acute HZ
[35,41]. However, a recent Cochrane Review found no
evidence for an impact of antiviral therapy on PHN,
with their efficacy for prevention of PHN considered
modest at best [42].
Previously, it has been shown that patients requiring
hospitalisation are likely to have more severe HZ or
PHN, and thus, hospital-discharge data provide a mea-
sure of more serious cases [2]. In the present study,
direct costs associated with inpatient care for an HZ
case were more than 20 times the cost for outpatient
care. In comparison, direct costs associated with inpati-
e n tc a r ef o raP H Ne p i s o d ew e r em o r et h a nf i v et i m e s
the cost for outpatient care. This illustrates the
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more serious cases of HZ and PHN, where patients may
require hospital care.
It is difficult to make direct comparisons between the
present study and studies carried out in other countries
to assess direct and indirect costs associated with HZ
and PHN because of differences in healthcare practices
and pricing. Nonetheless, as others have concluded, the
economic and social costs of managing HZ and its com-
plications represent an important burden on healthcare
services and society [43], a view with which we would
concur.
Our study had a number of limitations in addition to
those already discussed. The higher percentage of home
consultations in the very elderly, which may not have
been recorded in the SIMG database, may have led to
underestimation of incidence in the very old. Hospital-
discharge data do not state unequivocally that HZ or
PHN was the initial reason for hospitalisation, which
may have affected the estimates of disease burden. As
GP prescriptions could not be linked to specific PHN
diagnostic codes and the drugs may have been pre-
scribed for conditions other than PHN, outpatient costs
for PHN may have been overestimated. Indirect costs
were based solely on productivity losses due to absence
from work and were derived from expert opinion, an
approach that may limit the reliability of indirect cost
estimates. Experts agreed that HZ patients will usually
loose between 7 and 10 working days, while in case of
serious pain 10-15 working days are reasonably lost due
to PHN. Accordingly, the conservative assumption of 7
and 10 working days lost due to HZ and PHN, respec-
tively, was made in the estimate of indirect costs. How-
ever, all focus group specialists stressed the extreme
variability of the non-acute phase. Finally, when combin-
ing the results from the epidemiological and economic
parts of the study it was not possible to obtain a mea-
sure of the reliability of estimates of the total cost of
HZ and PHN (covariance between the different compo-
nents of the total variability was unknown).
Conclusions
In conclusion, this study has demonstrated that HZ and
related complications such as PHN impose a consider-
able disease and economic burden in Italy. While our
estimates of HZ incidence in the Italian population can
be considered robust, those for the proportion of
patients with HZ who develop PHN are likely to be
underestimates and would best be assessed in prospec-
tive studies. As HZ and PHN disproportionately affect
the elderly, without intervention the burden to patients
and society is likely to grow as the proportion of elderly
in the Italian population continues to increase.
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